FF
DAWN

FourThought Financial’s Day One Biopharmaceuticals DAWN Stock Holding History

FourThought Financial’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$37K Hold
1,850
– – 0.01% 690
2022
Q2 		$33K Buy
+1,850
New +$19.1K ﹤0.01% 734

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FourThought Financial's DAWN Position: Q3 2022 in Review

FourThought Financial held its Day One Biopharmaceuticals (DAWN) position steady in Q3 2022 at 1,850 shares worth $37K. The position accounts for 0.01% of the portfolio, ranked #690.

FourThought Financial first reported a position in DAWN in Q2 2022 and has held it in 2 quarters since. 93 funds tracked by Wall St. Rank hold DAWN as of Q3 2022.

  • FourThought Financial held 1,850 shares of Day One Biopharmaceuticals worth $37K as of Q3 2022.
  • FourThought Financial left its Day One Biopharmaceuticals share count unchanged in Q3 2022.
  • Day One Biopharmaceuticals made up 0.01% of FourThought Financial's portfolio in Q3 2022, its #690 holding.
  • FourThought Financial first reported a position in Day One Biopharmaceuticals in Q2 2022 and has held it in 2 quarters since.
  • 93 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.